KR20200017494A - Nk-92 세포를 사용하여 메르켈 세포 암종 (mcc)을 치료하는 방법 - Google Patents

Nk-92 세포를 사용하여 메르켈 세포 암종 (mcc)을 치료하는 방법 Download PDF

Info

Publication number
KR20200017494A
KR20200017494A KR1020207001266A KR20207001266A KR20200017494A KR 20200017494 A KR20200017494 A KR 20200017494A KR 1020207001266 A KR1020207001266 A KR 1020207001266A KR 20207001266 A KR20207001266 A KR 20207001266A KR 20200017494 A KR20200017494 A KR 20200017494A
Authority
KR
South Korea
Prior art keywords
cells
subject
administered
merkel cell
cell carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207001266A
Other languages
English (en)
Korean (ko)
Inventor
한스 클링게만
티엔 리
로렌스 보이셀
Original Assignee
난트케이웨스트, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 난트케이웨스트, 인크. filed Critical 난트케이웨스트, 인크.
Publication of KR20200017494A publication Critical patent/KR20200017494A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207001266A 2017-06-20 2018-06-19 Nk-92 세포를 사용하여 메르켈 세포 암종 (mcc)을 치료하는 방법 Ceased KR20200017494A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522335P 2017-06-20 2017-06-20
US62/522,335 2017-06-20
PCT/US2018/038308 WO2018236887A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Publications (1)

Publication Number Publication Date
KR20200017494A true KR20200017494A (ko) 2020-02-18

Family

ID=62875317

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207001266A Ceased KR20200017494A (ko) 2017-06-20 2018-06-19 Nk-92 세포를 사용하여 메르켈 세포 암종 (mcc)을 치료하는 방법

Country Status (9)

Country Link
US (1) US20200171087A1 (https=)
EP (1) EP3641790A1 (https=)
JP (1) JP2020524164A (https=)
KR (1) KR20200017494A (https=)
CN (1) CN110753551A (https=)
AU (1) AU2018288712A1 (https=)
CA (1) CA3066463A1 (https=)
IL (1) IL270838A (https=)
WO (1) WO2018236887A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134085B1 (en) 2013-11-01 2026-04-29 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Also Published As

Publication number Publication date
WO2018236887A1 (en) 2018-12-27
AU2018288712A1 (en) 2019-12-12
JP2020524164A (ja) 2020-08-13
CA3066463A1 (en) 2018-12-27
CN110753551A (zh) 2020-02-04
EP3641790A1 (en) 2020-04-29
US20200171087A1 (en) 2020-06-04
IL270838A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
Najafi et al. The current knowledge concerning solid cancer and therapy
Bajetta et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
Siu et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
US20150344577A1 (en) Agents for treating tumors, use and method thereof
JP2015505313A (ja) 癌を治療するための併用療法
KR20080105123A (ko) 개선된 항종양 치료
AU2016328683A1 (en) New therapeutic strategies against blood cancer
JP2018517759A (ja) カルボプラチンを含む組成物及び用途
ES2898681T3 (es) Amplificadores del canibalismo celular para la utilización para sensibilizar tumores a la terapia de radiación
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
KR20200017494A (ko) Nk-92 세포를 사용하여 메르켈 세포 암종 (mcc)을 치료하는 방법
CN115362253B (zh) 利用维奈托克增强t细胞的方法
KR20200017495A (ko) Nk-92 세포 및 il-15 효능제의 조합 요법
EP3810200B1 (en) Compositions for treating melanoma
HK40022820A (en) Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
JP2014221752A (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
Choi et al. SYNERGISTIC ANTICANCER EFFECT OF COMBINATION TREATMENT WITH MEK INHIBITOR AND PI3K/MTOR DUAL INHIBITOR IN CASTRATION-RESISTANT PROSTATE CANCER IN VIVO AND EX VIVO: PD32-08
KR101988124B1 (ko) 암 연관 섬유아세포 표적용 약학적 조성물
Husieva et al. Drug classification for the treatment of hematologic malignancies
HALL et al. Combination of cannabidiol with low-dose naltrexone increases the anticancer action of chemotherapyin vitroandin vivo
US20210186978A1 (en) Combination therapy
Njar et al. GALETERONE SHOWS ANTI-TUMOR ACTIVITY IN MULTIPLE PRE-CLINICAL MODELS THAT EXPRESS ANDROGEN RECEPTOR SPLICE VARIANTS, SUPPORTING CORRELATIVE PATIENT DATA SEEN IN ARMOR2: PD32-07

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201229

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230410

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I